<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEDROXYPROGESTERONE ACETATE/ESTRADIOL CYPIONATE</span><br/>(med-rox'y-pro-ges'te-rone/es-tra-di'ol)<br/><span class="topboxtradename">Lunelle<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">estrogen</span>; <span class="classification">progestin</span><br/><b>Prototype: </b>Estradiol/Progesterone<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg medroxyprogesterone/5 mg estradiol cypionate per 0.5 mL</p>
<h1><a name="action">Actions</a></h1>
<p>Progesterone prevents follicular maturation and ovulation. In addition, it induces morphological changes in the endometrium
         including thinning of its lining, which may result in decreased likelihood of implantation. Mechanism of action is not fully
         understood.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Contraceptive that may act by preventing follicular maturation and ovulation, thickening of the cervical mucus, which prevents
         passage of sperm into the uterus, and decreases ability of sperm to survive in an environment of altered endometrium.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hormonal contraception.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity of any component of the product; pregnancy (category X), suspicion of pregnancy; genital bleeding of unknown
         etiology; thrombophlebitis or history of thrombophlebitic disorders: CVA or coronary artery disease (CAD); liver dysfunction,
         jaundice associated with pregnancy or contraceptive use; carcinoma of the endometrium, breast or other known estrogen-dependent
         neoplasia; severe hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; valvular heart
         disease with complications; history of hypertension or hypertensive related diseases (i.e., renal disease or renal failure);
         liver dysfunction; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes mellitus; history of depression; disorders involving fluid retention; history of hyperlipidemia.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Contraception</span><br/><span class="rdage">Adult/</span><span class="rdage">Adolescent:</span> <span class="rdroute">IM</span> 0.5 mL q month or 28 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Shake vial or prefilled syringe vigorously before use to ensure a uniform suspension.</li>
<li>Give into the deltoid, gluteus maximus, or anterior thigh.</li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, dizziness. <span class="typehead">CV:</span> Hypertension, MI, thrombophlebitis. <span class="typehead">GI:</span> Abdominal pain, nausea, gallbladder disease, hepatic adenomas or benign liver tumors, enlarged abdomen. <span class="typehead">Endocrine:</span> Breast tenderness/pain. <span class="typehead">Hematologic:</span> Arterial thromboembolism. <span class="typehead"> Metabolic:</span> Weight gain. <span class="typehead">CNS:</span> Cerebral hemorrhage, cerebral thrombosis, depression, emotional lability, headache, nervousness. <span class="typehead">Respiratory:</span> Pulmonary embolism. <span class="typehead">Skin:</span> Acne, alopecia. <span class="typehead">Urogenital:</span> Amenorrhea, dysmenorrhea, menorrhagia, metrorrhagia, decreased libido, vaginal moniliasis, vulvovaginal disorders. (Also see
      <small>ORAL CONTRACEPTIVES</small>.) 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increase <span class="alt">BSP</span> retention, <span class="alt">prothrombin,</span>
<span class="alt">platelet aggregability,</span>
<span class="alt">thyroid-binding globulin,</span>
<span class="alt">PBI,</span>
<span class="alt">T4,</span>
<span class="alt">transcortin,</span>
<span class="alt">corticosteroid,</span>
<span class="alt">triglyceride,</span>
<span class="alt">phospholipid</span> levels; may increase <span class="alt">ceruloplasmin,</span>
<span class="alt">aldosterone,</span>
<span class="alt">amylase transferrin,</span>
<span class="alt">renin</span> activity; May decrease <span class="alt">antithrombin III,</span>
<span class="alt">T3 resin uptake,</span>
<span class="alt">serum folate,</span>
<span class="alt">glucose tolerance,</span>
<span class="alt">albumin,</span>
<span class="alt">vitamin B<sub>12</sub>;</span> may reduce <span class="alt">metapyrone</span> test response.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aminoglutethimide,</b>
<span class="classification">antibiotics</span>, <span class="classification">barbiturates</span>, <b>carbamazepine,</b>
<b>fosphenytoin,</b>
<b>griseofulvin,</b>
<b>modafinil,</b>
<b>oxcarbazepine,</b>
<b>phenytoin,</b>
<b>pioglitazone,</b>
<b>primidone,</b>
<span class="classification">protease inhibitors</span>, <b>rifampin,</b>
<b>rifabutin,</b>
<b>rifapentine,</b>
<b>topiramate,</b>
<b>troglitazone</b> may decrease contraceptive effectiveness; may decrease effectiveness of <span class="classification">oral hypoglycemic agents</span>, <b>clofibrate;</b> may increase toxicity of <b>cyclosporine;</b> may increase hypercoagulability with <b>aminocaproic acid;</b> may interfere with activity of <span class="classification">aromatase inhibitors</span>. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease contraceptive effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from IM site. <span class="typehead">Peak:</span> 110 d. <span class="typehead">Duration:</span> 1 mo. <span class="typehead">Distribution:</span> 86% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized by hydrolysis in liver. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 1415 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report immediately S&amp;S of thrombophlebitis or thromboembolism (e.g., pulmonary embolism, CVA, TIA, retinal
            embolism).
         </li>
<li>Monitor BP especially with preexisting hypertension.</li>
<li>Monitor weight and degree of fluid retention.</li>
<li>Monitor for S&amp;S of bronchospasm in asthma patients; notify physician immediately.</li>
<li>Lab tests: HgA<sub>1C</sub> q3mo, and frequent fasting blood glucose and postprandial blood glucose in diabetics; periodic lipid profile and liver function
            tests.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow the schedule for receiving this drug. Drug must be administered every 2830 d to remain effective.</li>
<li>Use alternative forms of barrier contraception while taking antibiotics.</li>
<li>Avoid smoking while using this form of contraception. Smoking greatly increases the risk of serious cardiovascular adverse
            effects.
         </li>
<li>Diabetics should closely monitor blood glucose for loss of glycemic control.</li>
<li>Do not use OTC drugs, including St. John's wort, vitamin C, or acetaminophen without consulting the physician.</li>
<li>Report episodes of calf pain or tenderness, shortness of breath, chest pain, visual disturbances, drooping eyelid, double
            vision, or any other unusual symptom to the physician.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>